Some genetic mutations can significantly alter the choice of treatment or signal that a cancer is more likely to become resistant to a treatment. In colorectal cancers, mutations in the KRAS gene may signal that a patient will not respond to drugs such as cetuximab or panitumumab.
Learn more about targeting KRAS.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Precision Medicine in Cancer - Medscape - Jul 15, 2021.
Comments